DNMT3A and acute myeloid leukemia: Furthermore, hemoglobin levels at AML diagnosis were higher in patients with ASXL1 mutation (10.5 vs. 8.9 g/dl, p=0.006), whereas platelet count was higher in patients with DNMT3A mutation (77 vs. 47×109/L, p=0.02).